W f
n a prime focus
worldwide, g towards ng new
, particularly m countries.
ernational cially look at h Asian and ies with ses or hips,
ASIA
Agilent Technologies Opens Service Centre in Vietnam
Agilent Technologies has opened an Advantage Services facility in Hanoi, Vietnam offering calibration and repair services for electronic test instruments.
The technicians and engineers who all speak the local language, are thoroughly trained and have access to Agilent factory engineers. Their calibration and repair processes incorporate the same automated procedures used at service centres and mobile calibration labs around the world.
The new centre adds to more than 50 service locations around the world for the company, making it one of the largest worldwide OEM service network providers with consistent
quality results for calibration and repair services.
"Whether your engineers are in Hanoi, Vietnam; Tel Aviv, Israel; or Roseville, California, USA, you can count on the same measurement results," said Franklin So, Agilent's Asia Region General Manager. "Our globally networked automated test procedures measure the actual performance of every warranted specification and adjust them if necessary."
The increased services network provides faster turn-around time by reducing customs delays when shipping between countries, the Company said.
More Info. 235
opportunities realising
by Heather Hobbs @
intlabmate.com to
her companies export markets.
Link Technologies Expands into the Far East
Link Technologies Ltd, a specialist manufacturer of oligonucleotide reagents and precursors, has announced Zirench Technology Co Ltd as distributor in China, the first Asian distributor for its comprehensive range of products. Located in Dalian City, Zirench Technology will provide invaluable local support for customers and expand services across the country.
The appointment is said to be the first signing of multiple, upcoming distributorship agreements in the Far East for Link and is testament to the company’s ongoing strategic development and growth. As an ISO 9001:2008 certified supplier of products for the BellsHill, Scotland-based company is committed to providing all customers with high purity, reliable oligo precursors and reagents.
ERT Expands Corporate Presence in Japan
ERT, a global technology-driven provider of health outcomes research services has announced significant milestones that reinforce its position as a leading eClinical trial solutions provider in Japan.
The Company has completed registration for Kabushiki Kaisha (KK) in Japan and has formed a fully-owned subsidiary, ERT Asia Group, Ltd enabling it to broaden the local services it provides in Japan and establish a solid foundation to expand its Asian presence. Along with this registration, ERT will grow the number of local resources that will work directly with its customers to deploy Japan-based projects.
“We are pleased to have collaborated with so many global and domestic biopharmaceutical organisations on their Japanese- based clinical trials and to have delivered the valuable data they need to evaluate their products’ safety and efficacy profiles,” said Robert Brown, Vice President, Business Development Asia-Pacific at ERT.
“Increasing the number of local ERT resources will enable us to work more collaboratively with our customers and our excellent partners in Japan and other Asian countries to increase efficiencies in study execution and improve the integrity of data collected in clinical research.”
More Info. 236 Endress+Hauser Consolidates Position in Indonesia
Following over two decades since it entered the Indonesian market, Endress+Hauser has strengthened its position since its long-time sales partner in Jakarta joined the Group on January 1st as an independent Endress+Hauser company.
“We are convinced that our own distribution company will allow us to serve our customers even better,” said Michael Ziesemer, COO of the Endress+Hauser Group. “Indonesia offers an interesting framework for future growth.”
Indonesia is the world’s largest archipelago country consisting of more than 17,000 islands stretching from Sumatra to Papua and is the fourth largest populated country in the world with more than 240 million people. The country’s economic growth has consistently been above 6% in the past years, one of the highest in the region. Endress+Hauser is active in all areas of process technology in Indonesia with focus on chemicals,
mining, oil & gas, water & wastewater, power & energy, as well as the food & beverage and the pulp & paper industry.
Endress+Hauser’s presence in Indonesia stretches back to 1991 when the company entered a partnership with a local representative, Grama Bazita. Today, what was once a small business has grown into a company with 100 employees. The head office in Jakarta, branches in Medan and Surabaya and offices in Pakanbaru, Bontang, Balikpapan and Semarang guarantee a strong support network.
“With its first-class range of products and services as well as a consistent focus on the needs of the customer, Endress+Hauser has set new standards in Indonesia,” said Rajesh Malhotra, Managing Director of the new Endress+Hauser sales centre. “The right time has come for us to continue to grow as a part of the Endress+Hauser Group.”
More Info. 238
Aggressive Strategies Confirm Big Pharma’s Indian Interest
The increasing number of consolidations and in-licensing agreements between Multinational Corporations (MNC) and Indian companies highlights the growing significance of the country’s pharmaceutical market, states business intelligence firm GBI Research. The company’s latest report* points to the introduction of product patents in 2005, 100% Foreign Direct Investment (FDI) in pharmaceuticals in 2006 and the strong growth prospects for generics and biosimilars in the country, as having been strong incentives to foreign investments.
Does your company sell or wish to sell laboratory products and services to the economies of Asia? Are you looking for local distributors and agents to represent you?
If so, why not advertise your products in our market-leading journal International Labmate. Contact us today for more information:
info@intlabmate.com
Mergers and Acquisitions between 2007 and 2012, added up to a value of around US$1 billion and approximately 400 partnerships were formed over the 2007-2012 period – the majority of which were valued at more than US$100 million. GBI Research also expects India’s pharmaceutical industry to grow as a result of rising income levels leading to higher treatment expectations. However, there are still some significant obstacles in providing a high level of healthcare across the country. For example, the country’s healthcare workforce is very small compared to its large population. Additionally drug counterfeiting has developed as a major concern within the sector, the report added.
* Indian Pharmaceutical Market Outlook - Enhanced Purchasing Power, Rural Market Penetration and Expanded Access to Healthcare Attracting Big Pharma Investment.
More Info. 239
Commenting on the new distributor agreement, Dr John Bremner, CEO at Link Technologies, said: “We are working hard to effectively deliver our products to customers in research and industrial institutions in Asia and other parts of the world, where easily accessible local support and expertise is very important. We are delighted that this deal with Zirench boosts this strategy.”
Dr Victor Liu, Commercial Manager at Zirench Technology, added “Our aim is to offer our customers laboratory instruments, supplies and biological agents of world-class quality. As such, we were keen to act on behalf of Link Technologies, to raise awareness of and distribute their high quality oligo precursor products across China.”
Providing a broad catalogue of reagents for DNA, RNA and PNA synthesis, Link Technologies has particular expertise in the manufacture of modified nucleic acid products, often unavailable elsewhere.
More Info. 237
Business
Opportunities
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96
